Vaxart, Inc. (NASDAQ:VXRT), a biotechnology company specializing in the development of oral recombinant vaccines with a market capitalization of approximately $159 million, announced on Monday an ...

As DOGE targets the Consumer Financial Protection Bureau, its workforce leader’s attempt to slow the process has resulted in ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

Investors often focus myopically on earnings, but a company's balance sheet — its financial strength, is also key.